As of 5 Jul 2026, Jubilant Pharmova share price is ₹971.30. The stock opened at ₹977.00, compared to its previous close of ₹973.20. During today's trading session, Jubilant Pharmova share price moved in the range of ₹963.00 to ₹979.95, with an average price of ₹971.48 for the day. Looking at its last 52-week, the stock has touched a low of ₹786.05 and a high of ₹1,248.00. On the performance front, Jubilant Pharmova share price has declined by 8.17% over the last six months and is down 19.33% on a year-on-year basis.
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹7,234.50 | ₹6,702.90 | ₹6,281.70 | ₹6,130.16 |
| Other Income | ₹56.80 | ₹68.70 | ₹38.30 | ₹11.29 |
| Total Revenue | ₹7,291.30 | ₹6,771.60 | ₹6,320.00 | ₹6,141.45 |
| Total Expenses | ₹6,669.70 | ₹6,456.30 | ₹6,247.70 | ₹5,501.02 |
| Profit Before Tax | ₹980.60 | ₹170.50 | ₹27.80 | ₹630.45 |
| Tax | ₹144.30 | ₹97.80 | ₹92.70 | ₹217.43 |
| Profit After Tax | ₹836.30 | ₹72.70 | -₹64.90 | ₹413.02 |
| EPS - Basic | ₹52.99 | ₹4.87 | -₹3.83 | ₹26.00 |
| EPS - Diluted | ₹52.85 | ₹4.86 | -₹3.83 | ₹26.00 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹980.60 | ₹170.50 | ₹27.80 | ₹630.45 |
| Income before WC changes | ₹1,198.70 | ₹925.90 | ₹810.70 | ₹1,209.92 |
| Change in Assets | ₹73.50 | ₹197.00 | ₹118.00 | -₹135.57 |
| Change in Liabilities | ₹38.30 | ₹56.10 | -₹63.70 | -₹42.71 |
| Change in WC | ₹111.80 | ₹253.10 | ₹54.30 | -₹178.29 |
| Cash flow from Operations | ₹1,072.10 | ₹971.30 | ₹660.70 | ₹837.54 |
| Cash flow from Investing | ₹487.70 | -₹607.90 | -₹544.40 | -₹380.37 |
| Cash flow from Financing | -₹1,452.70 | -₹432.50 | -₹156.70 | -₹32.60 |
| Total Cash Flow | ₹131.90 | -₹57.50 | ₹30.10 | ₹481.86 |
| Cash (Start of the year) | ₹956.40 | ₹1,013.90 | ₹983.80 | ₹501.96 |
| Cash (End of the year) | ₹1,088.30 | ₹956.40 | ₹1,013.90 | ₹983.82 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹9,179.20 | ₹7,672.40 | ₹7,394.30 | ₹6,481.68 |
| Current Assets | ₹3,577.20 | ₹3,876.10 | ₹3,762.40 | ₹3,509.19 |
| Total Assets | ₹12,756.40 | ₹11,548.50 | ₹11,156.70 | ₹9,990.87 |
| Current Liabilities | ₹2,164.60 | ₹1,889.00 | ₹1,772.40 | ₹1,591.60 |
| Net Current Asset | ₹1,412.60 | ₹1,987.10 | ₹1,990.00 | ₹1,917.59 |
| Non-Current Liabilities | ₹4,353.20 | ₹4,238.40 | ₹3,992.50 | ₹3,082.87 |
| Equity Capital | ₹6,238.60 | ₹5,421.10 | ₹5,391.80 | ₹5,316.40 |
| Total Equity & Liabilities | ₹12,756.40 | ₹11,548.50 | ₹11,156.70 | ₹9,990.87 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹745.70 | ₹784.70 | ₹810.10 | ₹725.73 |
| Other Income | ₹99.60 | ₹103.40 | ₹137.90 | ₹126.16 |
| Total Revenue | ₹845.30 | ₹888.10 | ₹948.00 | ₹851.89 |
| Total Expenses | ₹796.50 | ₹846.40 | ₹868.70 | ₹767.17 |
| Profit Before Tax | ₹37.60 | ₹41.70 | ₹79.30 | ₹84.72 |
| Tax | ₹18.40 | ₹10.10 | ₹29.40 | ₹4.23 |
| Profit After Tax | ₹19.20 | ₹31.60 | ₹49.90 | ₹80.49 |
| EPS - Basic | ₹1.21 | ₹1.99 | ₹3.13 | ₹5.05 |
| EPS - Diluted | ₹1.21 | ₹1.99 | ₹3.13 | ₹5.05 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹37.60 | ₹41.70 | ₹79.30 | ₹84.72 |
| Income before WC changes | ₹116.80 | ₹89.90 | ₹44.10 | ₹36.04 |
| Change in Assets | ₹24.30 | ₹71.50 | -₹55.90 | -₹57.39 |
| Change in Liabilities | ₹7.00 | -₹6.00 | -₹35.90 | ₹53.97 |
| Change in WC | ₹31.30 | ₹65.50 | -₹91.80 | -₹3.42 |
| Cash flow from Operations | ₹135.60 | ₹143.20 | -₹65.10 | -₹3.55 |
| Cash flow from Investing | -₹2.30 | -₹40.30 | ₹31.10 | ₹93.10 |
| Cash flow from Financing | -₹156.80 | -₹77.80 | ₹22.50 | -₹107.37 |
| Total Cash Flow | -₹23.50 | ₹25.10 | -₹11.50 | -₹17.82 |
| Cash (Start of the year) | ₹36.10 | ₹11.00 | ₹22.50 | ₹40.35 |
| Cash (End of the year) | ₹12.60 | ₹36.10 | ₹11.00 | ₹22.53 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹2,425.40 | ₹2,451.30 | ₹2,429.60 | ₹2,369.75 |
| Current Assets | ₹484.20 | ₹540.60 | ₹578.80 | ₹525.81 |
| Total Assets | ₹2,909.60 | ₹2,991.90 | ₹3,008.40 | ₹2,895.56 |
| Current Liabilities | ₹310.30 | ₹315.40 | ₹361.20 | ₹252.26 |
| Net Current Asset | ₹173.90 | ₹225.20 | ₹217.60 | ₹273.55 |
| Non-Current Liabilities | ₹281.20 | ₹302.00 | ₹232.70 | ₹204.23 |
| Equity Capital | ₹2,318.10 | ₹2,374.50 | ₹2,414.50 | ₹2,439.07 |
| Total Equity & Liabilities | ₹2,909.60 | ₹2,991.90 | ₹3,008.40 | ₹2,895.56 |
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals, including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical businesses working to address unmet medical needs in oncology and autoimmune diseases.
Jubilant Pharmova share price is ₹971.30 as on 03 Jul, 2026, 15:29 IST.
In the last 1 year, Jubilant Pharmova delivered a return of -19.33%. The Jubilant Pharmova share price hit a high of ₹1,248.00 and low of ₹786.05.
The Mutual Fund Shareholding in Jubilant Pharmova was 8.03% at the end of Mar 2026.
The 52-week high and low of Jubilant Pharmova share is ₹1,248.00 and ₹786.05 as of 03 Jul, 2026.
The market capitalisation of Jubilant Pharmova is ₹15,494.30 Crores as on 03 Jul, 2026.
The stock symbol of Jubilant Pharmova is JUBLPHARMA on the NSE, 530019 on the BSE, and the ISIN is INE700A01033.
Jubilant Pharmova shares closed yesterday at ₹973.20 on NSE & ₹972.65 on BSE
To buy Jubilant Pharmova shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
No, shares of Jubilant Pharmova or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Jubilant Pharmova shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
The PE and PB ratio of Jubilant Pharmova is 38.98 and 2.18 respectively, as on 03 Jul, 2026, 15:29 IST.